{"entity":{"id":"cancerfind","kind":"drug","name":"CancerFind","aka":[],"tldr":"IMBdx's blood test from South Korea, offered at screening centres there, which in a laboratory study detected nine in ten cancers including stage I.","summary":"In Jeong et al. (Experimental and Molecular Medicine 2026; 1,415 samples, eight cancer types and healthy controls, case-control) the model had 93.2% sensitivity at 95% specificity, 92.3% at stage I, and 85.7% accuracy for the tissue of origin within its top two calls. IMBdx told Korean press (Asia Economy, 1 October 2025) that the test had expanded from 8 to 12 cancer types, with 98.0% specificity and 89.3% sensitivity, and was offered at 103 screening centres and medical institutions; those are company statements. No Korean MFDS status or price was found.","status":"emerging","asOf":"2026-10-29","links":[{"label":"Jeong et al., Experimental and Molecular Medicine 2026","url":"https://doi.org/10.1038/s12276-026-01674-7"},{"label":"Kim et al., Experimental and Molecular Medicine 2023","url":"https://doi.org/10.1038/s12276-023-01119-5"},{"label":"Asia Economy, 1 October 2025","url":"https://view.asiae.co.kr/en/article/2025100114010388952"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","cfdna-methylation-testing","fragmentomics"],"targets":[],"drugs":[],"companies":["imbdx"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","Case-control figures at 95% specificity: in a screening population about 5 in 100 people without cancer would test positive at that threshold.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"CancerFind","modality":"Multi-cancer early detection blood test (whole-genome methylation sequencing with fragmentomics)","mechanism":"Whole-genome methylation sequencing of cell-free DNA, combining average methylation, copy number and fragment size in an ensemble model, with a predicted tissue of origin.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cancerfind/","neighbours":{"technology":[{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/"},{"id":"fragmentomics","kind":"technology","name":"cfDNA fragmentomics","route":"/technologies/fragmentomics/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"company":[{"id":"imbdx","kind":"company","name":"IMBdx","route":"/companies/imbdx/"}]}}